Glutamine synthetase (GS) (GS)

Glutamine synthetase (GS), also known as glutamate-ammonia ligase, is an essential enzyme that catalyzes the ATP-dependent conversion of glutamate and ammonia into glutamine (UniProt P15104). This reaction is the primary pathway for ammonia detoxification in the body, particularly in the brain and liver (PubMed: 25851653). In the central nervous system, GS is primarily expressed in astrocytes, where it plays a vital role in the glutamate-glutamine cycle by recycling the excitatory neurotransmitter glutamate (PubMed: 22015515). Dysregulation of GS activity is associated with several clinical conditions, including hepatic encephalopathy, where impaired ammonia clearance leads to cognitive deficits, and epilepsy, where GS deficiency results in glutamate accumulation (PubMed: 23103412). Furthermore, certain cancers exhibit glutamine addiction and upregulate GS to support rapid proliferation, making the enzyme a potential therapeutic target in oncology (PubMed: 28273111). L-methionine sulfoximine (MSO) is a classic, irreversible inhibitor of GS that acts as a transition-state analog; it is phosphorylated by the enzyme to form MSO-phosphate, which binds tightly to the active site (PubChem CID 4001). While MSO is a powerful tool in biochemical research, its clinical application is hindered by its ability to induce seizures due to the disruption of brain nitrogen homeostasis (PubMed: 11518991).

Other names

Glutamate-ammonia ligaseGLULGlutamine synthase

Irreversible inhibition via transition-state mimicry; the inhibitor is phosphorylated by the enzyme, creating a stable complex that blocks the active site.